The Latest Cardiac and Vascular News
SAN CARLOS, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) — BioCardia®, Inc. [NASDAQ: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results and business highlights for the second quarter of 2020 and filed its quarterly report on Form 10-Q for the three and six months […]
First Site Initiation Visit in Trial Completed and Executive Steering Committee Named SAN CARLOS, Calif., July 01, 2020 (GLOBE NEWSWIRE) — BioCardia®, Inc. [NASDAQ:BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced activation of a pivotal trial studying the Company’s investigational CardiAMP® cell therapy in the treatment of […]
SAN CARLOS, Calif., June 29, 2020 (GLOBE NEWSWIRE) — BioCardia®, Inc., (OTC: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the Company has resumed cases in the CardiAMP Heart Failure Trial. The first patient procedure completed since elective procedures were paused due to […]
SAN CARLOS, Calif., June 17, 2020 (GLOBE NEWSWIRE) — BioCardia®, Inc. NasdaqCM: BCDA (the “Company”), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the pricing of its public offering of 4,762,000 shares of common stock at a price to the public of $2.10 per share. BioCardia […]
SAN CARLOS, Calif., May 15, 2020 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results and business highlights for the first quarter of 2020 and filed its quarterly report on Form 10-Q for the three months ended March […]
Plans IND Submission for Same Cells to Treat COVID-19 Induced Acute Respiratory Distress Syndrome AN CARLOS, Calif., May 05, 2020 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced data from a recent animal study performed by the Company that […]
SAN CARLOS, Calif., April 30, 2020 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported that it has accepted and implemented FDA-recommended modifications to the primary endpoint for the CardiAMP® Cell Therapy Heart Failure Trial and associated statistical analysis plan. […]
SAN CARLOS, Calif., April 28, 2020 (GLOBE NEWSWIRE) — BioCardia®, Inc., (OTC: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the issuance of United States Patent No. 10,632,281, entitled “Drug Delivery Catheters that Attach to Tissue and Methods for Their Use.” This new […]
SAN CARLOS, Calif., April 14, 2020 (GLOBE NEWSWIRE) — BioCardia®, Inc. (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported it has entered into an agreement for litigation financing which has been filed today with the Securities and Exchange Commission on Form 8-K. BioCardia, Inc. […]
Company to Host Conference Call with National Co-Principal Investigators Today at 4:15 p.m. ET to Provide Study Updates SAN CARLOS, Calif., March 31, 2020 (GLOBE NEWSWIRE) — BioCardia (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the independent Data Safety Monitoring Board (DSMB) […]
